Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency

References

• Morales A, Bain J, Ruijs A, Chapdelaine A, Tremblay R R. Clinical practice guidelines for screening and monitoring male patients receiving testosterone supplementation therapy. Int J Impotence Res 1996; 8: 95–7
   PubMedGoogle Scholar
• Vermeulen A. The male climacterium. Ann Med 1993; 25: 531–4
   PubMed Web of Science ®Google Scholar
• Kaufman J M. Androgens, bone metabolism and osteoporosis. Androgens and the Aging Male., B Oddens, A Vermeulen. Parthenon Publishing, CarnforthUK 1996; 39–63
   Google Scholar
• Schow D A, Redmon B, Pryor J L. Male menopause. How to define it, how to treat it. Male Menopause 1997; 101: 62–79
   Google Scholar
• Hajjar R R, Kaiser F E, Morley J E. Outcomes of long–term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997; 82: 3793–6
   PubMed Web of Science ®Google Scholar
• Dobs A S, Hoover D R, Chen M C, Allen R. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study. J Clin Endocrinol Metab 1998; 83: 33–9
   PubMed Web of Science ®Google Scholar
• Kaiser F E, Morley J E. Gonadotropins, testosterone, and the aging male. Neurobiol Aging 1994; 15: 559–63
   PubMed Web of Science ®Google Scholar
• Fall C, Hindmarsh P, Dennison E, Kellingray S, Barker D, Cooper C. Programming of growth hormone secretion and bone mineral density in elderly men: a hypothesis. J Clin Endocrinol Metab 1998; 83: 135–9
   PubMed Web of Science ®Google Scholar
• Toogood A A, O'Neill P A, Shalet S M. Beyond the somatopause: growth hormone deficiency in adults over the age of 60 years. J Clin Endocrinol Metab 1996; 81: 460–5
   PubMed Web of Science ®Google Scholar
• Guazzo E P, Kirkpatrick P K, Goodyer I M, Shiers H M, Herbert J. Cortisol, dehydroepi–androsterone (DHEA) and DHEA sulfate in the cerebrospinal fluid of man: relation to blood levels and the effects of age. J Clin Endocrinol Metab 1996; 81: 3951–60
   PubMed Web of Science ®Google Scholar
• Morales A J, Nolan J J, Nelson J C, Yen S SC. Effect of replacement dose of dehydroepiandrosterone in men and in women of advancing age. J Clin Endocrinol Metab 1994; 78: 1360–7
   PubMed Web of Science ®Google Scholar
• Parker C R, Mixon R L, Brissie R M, Grizzle W E. Aging alters zonation in the adrenal cortex of men. J Clin Endocrinol Metab 1997; 82: 3898–901
   PubMed Web of Science ®Google Scholar
• Morley J E, Kaiser F, Raum W J, et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy male: progressive decrease in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin–like growth factor 1 to growth hormone. Proc Natl Acad Sci USA 1997; 94: 7537–42
   PubMed Web of Science ®Google Scholar
• Stearns E L, MacDonald J A, Kaulfman B J, Lucman T S, Winter J S, Faiman C. Declining testicular function with age, hormonal and clinical correlates. Am J Med 1974; 57: 761–4
   PubMed Web of Science ®Google Scholar
• Kaler L W, Neaves W B. Attrition of the human Leydig cell population with advancing age. Anat Rec 1978; 192: 513–17
   PubMedGoogle Scholar
• Winters S J, Troen P. Episodic luteinizing hormone (LH) secretion and the response of LH and follicle stimulating hormone to LH–releasing hormone in aged men: evidence for coexistent primary testicular insufficiency and an impairment in gonadotropin secretion. J Clin Endocrinol Metab 1982; 55: 560–8
   PubMed Web of Science ®Google Scholar
• Bremner W J, Vitiello M V, Prinz P N. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983; 56: 1278–84
   PubMed Web of Science ®Google Scholar
• Harman S M, Tsitouras P D. Reproductive hormones in aging men. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. J Clin Endocrinol Metab 1980; 51: 35–40
   PubMed Web of Science ®Google Scholar
• Gooren L JG. A ten–year safety study of the oral androgen testosterone undecanoate. J Androl 1994; 15: 212–215
   PubMed Web of Science ®Google Scholar
• Hajjar R R, Kaiser F E, Morley J E. Outcomes of long–term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997; 82: 3793–6
   PubMed Web of Science ®Google Scholar
• Wang C, Eyre D R, Clark R, et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3654–62
   PubMed Web of Science ®Google Scholar
• Dobbs A S, Hoover D R, Chen M C, Allen R. Pharmacokinetic characteristics, efficacy and safety of buccal testosterone in hypogonadal males: a pilot study. J Clin Endocrinol Metab 1988; 83: 33–9
   Google Scholar
• Meikle A W, Mazer N A, Moellmer J F. Enhanced transdermal delivery of testosterone across non scrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 1992; 74: 623–8
   PubMed Web of Science ®Google Scholar
• Bardin C W, Swerdloff R S, Sauten R. Androgens: risks and benefits. J Clin Endocrinol Metab 1991; 73: 4–7
   PubMed Web of Science ®Google Scholar
• Cauley S A, Gutai J P, Kuller L H, Dai S. Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol 1987; 60: 771–7
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Khaw K S. Endogenous sex hormone levels and cardiovascular disease in men. A prospective population based study. Circulation 1998; 78: 539–43
   Google Scholar
• Phillips G B, Pinkerneil B H, Jing T Y. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994; 14: 701–6
   PubMed Web of Science ®Google Scholar
• Hromadova M, Hacik T, Malarinsky E, Riecansky I. Alterations oflipid metabolism in men with hypotestosteronemia. Horm Metab Res 1991; 23: 392–4
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Kaufman J M. Androgens and cardiovascular disease in men and women. Aging Male 1998; 1: 35–50
   Google Scholar
• Morales A J, Nolan J J, Nelson J P, Yen S S. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78: 1360–7
   PubMed Web of Science ®Google Scholar
• Wang C, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men. A clinical research center study. J Clin Endocrinol Metab 1996; 81: 3578–83
   PubMed Web of Science ®Google Scholar
• Morales A, Johnston B, Heaton J PW, Lundie M. Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J Urol 1997; 157: 849–54
   PubMed Web of Science ®Google Scholar
• Meikle W A, Stephenson R A, Lewis C M, et al. Effects of age and sex hormones on transition and peripheral zone volumes of prostate in benign prostatic hyperplasia in twins. J Clin Endocrinol Metab 1997; 82: 571–5
   PubMed Web of Science ®Google Scholar
• Thomas J A, Keenan E J. Effects of estrogens on the prostate. J Androl 1994; 15: 97–9
   PubMedGoogle Scholar
• Behre H M. Prostate volume in treated and untreated hypogonadal men in comparison to age–matched normal controls. Clin Endocrinol 1994; 40: 341–9
   PubMed Web of Science ®Google Scholar
• Nomura A, Heilrunn L K, Stemmermann G N, et al. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 1988; 48: 3515–17
   PubMed Web of Science ®Google Scholar
• Ornstein D K, Smith D S, Humphrey P A, Catalona W J. The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. J Urol 1998; 159: 1234–7
   PubMed Web of Science ®Google Scholar
• Pannek J, Rittenhouse H G, Chan D W, Epstein J I, Walsh P C, Partin A W. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol 1998; 159: 1238–42
   PubMed Web of Science ®Google Scholar
• Irani J, Millet C, Levillain P, Dore B, Begon F, Aubert J. Serum–to–urinary prostate specific antigen ratio: its impact in distinguishing prostate cancer when serum prostate specific antigen level is 4 to 10 ng/ml. J Urol 1997; 157: 185–8
   PubMed Web of Science ®Google Scholar
• Partin A W, Catalona W J, Southwick P C, Subong E N, Gasior G H, Chan D W. Analysis of percent free prostate specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume and age. Urology 1996; 48: 55–62
   PubMed Web of Science ®Google Scholar
• Berry S J, Coffey D S, Walsh P C, Ewing L L. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474–9
   PubMed Web of Science ®Google Scholar
• Lowe B A, Listrom M B. Incidental carcinoma of the prostate: an analysis of the predictors of progression. J Urol 1988; 140: 1340–4
   PubMed Web of Science ®Google Scholar
• Holmang S. Effect of long term oral testosterone undecanoate treatment on prostate volume and serum prostate specific antigen concentration in eugonadal middle–age men. Prostate 1993; 23: 99–106
   PubMed Web of Science ®Google Scholar
• Tenover J S. Androgen administration to aging men. Endocrinol Metab Clin N Am 1994; 23: 877–92
   PubMed Web of Science ®Google Scholar
• Tenover J S. Androgen deficiency in aging men. Presented at the. VI International Congress of Andrology. Salzburg. May, 1997
   Google Scholar